Penicillin G benzathine Injection - Uses, Dose (Syphilis, RF), Side effects

Penicillin G benzathine (Penidure LA) is a long-acting formulation of penicillin for intramuscular use in the prevention of rheumatic fever and treatment of a variety of infections including syphilis.

Penicillin G benzathine Uses:

  • Acute glomerulonephritis:

    • Secondary prophylaxis with a history of acute glomerulonephritis
  • Respiratory tract infections:

    • Treatment for streptococcal upper respiratory tract infections (including pharyngitis) that are mild to moderate and responsive to low, prolonged serum penicillin G concentrations.
  • Rheumatic fever and chorea:

    • Secondary prophylaxis of rheumatic fever and/or chorea
  • Rheumatic heart disease:

    • Secondary prophylaxis in patients with rheumatic heart disease
  • Syphilis and other venereal diseases:

    • Treatment of syphilis, yaws, bejel, and pinta
  • Off-Label Use of Penicillin G benzathine in Adults:

    • Streptococcal (group A) chronic carriage

Penicillin G benzathine Dose in Adults

Penicillin G benzathine Usual dosage range:

  • IM: Single dose of 1.2 to 2.4 million units

Streptococcus (group A):

Penicillin G benzathine Dose in the treatment of acute Pharyngitis:

  • IM: 1.2 million units as a stat single dose

Penicillin G benzathine Dose in the Secondary prophylaxis for rheumatic fever (prevention of recurrent attacks):

  • IM: 1.2 million units once every 21 to 28 days.
  • The duration of prophylaxis depends on risk factors and the presence of valvular heart disease.
  • Manufacturer's labeling:

    • The dosing recommended in drug literature could not correspond to current clinical guidelines.
    • IM: 600,000 units every 2 weeks

Penicillin G benzathine Dose in the Secondary prophylaxis of glomerulonephritis:

  • IM: 1.2 million units every 4 weeks or 600,000 units twice monthly

Penicillin G benzathine Dose in the treatment of Chronic carriage (off-label):

  • IM: 1.2 million units as a stat single dose in combination with oral rifampin.
  • Note: Most individuals with chronic carriage do not require antibiotics.

Penicillin G benzathine Dose in the treatment of Syphilis:

  • Primary, Secondary, Early Latent (<1 year duration):

    • IM: 2.4 million units as a single dose
  • Late Latent, Latent with unknown duration, or Tertiary Syphilis (with normal CSF examination):

    • IM: 3 doses of 2.4 million units once a week

Penicillin G benzathine Dose in the treatment of Neurosyphilis (including Ocular Syphilis):

  • Not indicated for initial treatment;
  • aqueous penicillin G IV is preferred initial therapy (refer to Penicillin G Parenteral/Aqueous monograph for dosing).
  • To offer a comparable overall duration of therapy to that for latent syphilis after penicillin G IV first treatment, one may consider administering penicillin G benzathine 2.4 million units IM once weekly for 3 weeks.

Penicillin G benzathine Dose in the treatment of Yaws, bejel, and pinta:

  • IM: 1.2 million units as a single dose

Penicillin G benzathine Dose in Children

Penicillin G benzathine dose in Group A streptococcal upper respiratory infection:

  • Infants, Children, and Adolescents: IM:

    • Primary prevention of Rheumatic fever:

      • ≤27 kg: 600,000 units as a single dose
      • >27 kg: 1.2 million units as a single dose
    • Secondary prevention of Rheumatic fever:

Note:

  • Duration of secondary rheumatic fever prophylaxis varies:
    • Rheumatic fever with carditis and residual heart disease:
      • 10 years, sometimes lifelong prophylaxis, or until age 40, whichever comes first;
    • rheumatic fever with carditis but no residual heart disease:
      • 10 years, or for the duration of 21 years, whichever comes first;
    • rheumatic fever without carditis:
      • Until the older of five years or 21. (whichever is longer)
      • ≤27 kg: For 3-4 weeks, 600,000 units 
      • >27 kg: For 3-4 weeks, 1.2 million units 

Penicillin G benzathine Dose in the treatment of Syphilis:

  • Infants, Children, and Adolescents: IM

    • Primary, Secondary, or Early Latent (< 1-year duration):

      • 50,000 units/kg once;
      • The maximum dose: 2.4 million units
    • Late Latent or Latent with unknown duration:

      • 50,000 units/kg once weekly for 3 doses;
      • The maximum dose: 2.4 million units

Penicillin G benzathine Pregnancy Risk Category: B

  • Animal reproduction studies have not shown any adverse events.
  • Penicillin G benzathine crosses over to the placenta.
  • Penicillins used by mothers have not been shown to increase the risk of adverse effects on fetus. Penicillin G is the preferred drug for the treatment of syphilis in pregnancy.

Penicillin G benzathine use during breastfeeding:

  • Breast milk contains soluble penicillin G.
  • The manufacturer suggests that nursing mothers exercise caution when using penicillin.
  • Other effects that are not related to the dose include altered bowel flora or allergic sensitization.

Penicillin G benzathine Dose in Kidney Disease:

  • There are no dosage adjustments provided in the drug manufacturer’s labeling;
  • use with caution.

Penicillin G benzathine Dose in Liver Disease:

  • There are no dosage adjustments provided in the drug manufacturer’s labeling;
  • use with caution.

Side effects of Penicillin G benzathine:

  • Cardiovascular:

    • Cerebrovascular Accident
    • Hypotension
    • Palpitations
    • Syncope
    • Tachycardia
    • Vasodilation
    • Vasospasm
    • Vasodepressor Syncope
  • Central Nervous System:

    • Anxiety
    • Coma
    • Confusion
    • Dizziness
    • Drowsiness
    • Euphoria
    • Fatigue
    • Headache
    • Localized Warm Feeling
    • Nervousness
    • Neurologic Abnormality (Neurogenic Bladder)
    • Numbness
    • Pain
    • Seizure
    • Transverse Myelitis
  • Dermatologic:

    • Diaphoresis
    • Gangrene Of Skin Or Other Tissue
    • Pallor
    • Skin Mottling
    • Skin Ulceration At Injection Site
  • Gastrointestinal:

    • Bloody Stools
    • Intestinal Necrosis
    • Nausea
    • Vomiting
  • Genitourinary:

    • Hematuria
    • Impotence
    • Priapism
    • Proteinuria
  • Hematologic & Oncologic:

    • Local Hemorrhage (At Injection Site)
    • Lymphadenopathy
  • Hepatic:

    • Increased Serum AST
  • Hypersensitivity:

    • Hypersensitivity Reaction
  • Immunologic:

    • Jarisch-Herxheimer Reaction
  • Local:

    • Abscess At Injection Site
    • Atrophy At Injection Site
    • Bruising At Injection Site
    • Cellulitis At Injection Site
    • Localized Edema (At Injection Site)
    • Inflammation At Injection Site
    • Injection Site Reaction (Neurovascular Damage)
    • Pain At Injection Site
    • Residual Mass At Injection Site
    • Tissue Necrosis At Injection Site
  • Neuromuscular & Skeletal:

    • Arthropathy
    • Exacerbation Of Arthritis
    • Periosteal Disease (Periostitis)
    • Rhabdomyolysis
    • Tremor
    • Weakness
  • Ophthalmic:

    • Blindness
    • Blurred Vision
  • Renal:

    • Increased Blood Urea Nitrogen
    • Increased Serum Creatinine
    • Myoglobinuria
    • Renal Failure
  • Respiratory:

    • Cyanosis

Contraindications to Penicillin G benzathine:

  • Hypersensitivity/ Allergy To Penicillins Or Any Component of The Formula

Warnings and precautions

  • Hypersensitivity reactions

    • Patients on penicillin have experienced severe and sometimes fatal hypersensitivity/ anaphylactic reactions.
    • This is especially true if patients have a history beta-lactam hypersensitivity (including cephalosporins), sensitivity to numerous allergens or IgE-mediated responses such as anaphylaxis or angioedema.
    • Serious allergic or anaphylactic reactions necessitate immediate emergency care, including the delivery of oxygen, epinephrine, steroids intravenously, and airway control, including intubation as needed.
  • Superinfection

    • Extended use can result in fungal and bacterial superinfections including pseudo-membranous collitis and C. difficile-associated diarrhoea (CDAD).
    • After more than two months of post-antibiotic therapy, CDAD was noticed.
  • Renal impairment

    • Patients with impaired renal function should be cautious.
  • Seizure disorders:

    • Patients who have a history of epilepsy should take extra care.
    • High uric acid levels can make people more likely to have seizures, especially if they have renal impairment.
  • Use of Syphilis or Neurosyphilis:

    • AAP and CDC don't recommend penicillin G benzathine as a first treatment for neurosyphilis and congenital syphilis. This is due to treatment failures, lack of published data and insufficient clinical evidence.

Penicillin G benzathine (long-acting intramuscular): Drug Interaction

Risk Factor C (Monitor therapy)

Acemetacin

Could raise the serum level of penicillins.

BCG Vaccine (Immunization)

Antibiotics may reduce the BCG vaccine's therapeutic effect (Immunization).

Lactobacillus and Estriol

The therapeutic effects of Lactobacillus and Estriol may be reduced by antibiotics.

Methotrexate

Penicillins may raise the level of methotrexate in the serum.

Mycophenolate

The serum levels of the active metabolite(s) of mycophenolate may drop when penicillins are used. Enterohepatic recirculation appears to be hindered, which has this impact.

Nitisinone

OAT1/3 Substrates' serum concentration can rise.

Pretomanid

OAT1/3 Substrates' serum concentration can rise.

Probenecid

Could raise the serum level of penicillins.

Teriflunomide

OAT1/3 Substrates' serum concentration can rise.

Vitamin K Antagonists (eg, warfarin)

The anticoagulant impact of vitamin K antagonists may be strengthened by penicillins.

Risk Factor D (Consider therapy modification)

Sodium Picosulfate

Antibiotics may reduce Sodium Picosulfate's therapeutic impact. Management: If a patient previously used or is currently using an antibiotic, think about utilising an alternative product for bowel cleansing prior to a colonoscopy.

Tetracyclines

May reduce penicillins' therapeutic efficacy.

Tolvaptan

OAT1/3 Substrates' serum concentration can rise. Treatment: Patients taking the Jynarque brand of tolvaptan should refrain from taking OAT1/3 substrates concurrently. With any combined use, it would be predicted that OAT1/3 substrate concentrations and effects would rise.

Typhoid Vaccine

The Typhoid Vaccine's therapeutic benefits may be reduced by antibiotics. The only strain impacted is the live attenuated Ty21a strain. Treatment: Patients receiving systemic antibacterial drugs should refrain from receiving the live attenuated typhoid vaccination (Ty21a). It is recommended to wait at least 3 days following the last dose of antibacterial medication before administering this vaccine.

Risk Factor X (Avoid combination)

BCG (Intravesical)

Antibiotics may impair the therapeutic benefit of BCG (Intravesical).

Cholera Vaccine

The therapeutic benefit of the cholera vaccine may be reduced by antibiotic use. Management: Avoid cholera vaccination in patients receiving systemic antibiotics, and within 14 days following the administration of oral or parenteral antibiotics.

Monitoring Parameters:

  • Observe for signs and symptoms of anaphylaxis during the first dose of administration.

How to administer Penicillin G benzathine?

  • Warm to room temperature before IM administration to lessen the pain associated with the injection.
  • Deep IM injection administration is done at a slow, steady rate in the dorso-gluteal region (upper outer quadrant of the buttock) or the ventro-gluteal region.
  • Do not inject near an artery or a nerve;
  • It can cause permanent neurological damage or gangrene.
  • When doses are repeated, rotate the injection site.
  • Do not administer IV, intra-arterially, or SubQ.

Mechanism of action of Penicillin G benzathine:

  • Interferes in the synthesis and maintenance of the bacterial cell walls during active multiplication, resulting in cell death and bactericidal activity.

Duration:

  • 1 to 4 weeks (dose-dependent); larger doses result in more sustained levels

Absorption:

  • IM: Slow

Distribution:

  • Minimal concentrations attained in CSF with inflamed or uninflamed meninges;
  • The highest levels are found in the kidney;
  • lesser amounts observed in liver, skin, intestines

Protein Binding:

  • ~60%

Time to peak serum concentration:

  • Within 12 to 24 hours;
  • serum levels are usually detectable for 7 to 28 days depending on the dose; larger doses result in more sustained levels rather than higher levels

Excretion:

  • Excreted by renal tubular excretion;
  • penicillin G can be found in urine for up to 12 weeks after a single IM injection;
  • renal clearance is delayed in neonates, young infants, and patients with impaired renal function

International Brands of Penicillin G benzathine:

  • Bicillin L-A
  • Bencelin
  • Benzapen
  • Benzetacil
  • Benzetacil L.A.
  • Benzibiotic
  • Bepeben
  • Bicillin G
  • Bicillin L-A
  • Debecylina
  • Deposilin
  • Extencilline
  • Indopen
  • Lentocilin-S
  • Leomypen
  • Longacillin
  • Mycin
  • Noraben
  • Pebenzatil
  • Pen Di Ben
  • Penadur
  • Penadur - LA
  • Penadur LA
  • Pencom
  • Pendepon
  • Pendiben L-A
  • Pendysin
  • Penidure
  • Penilente
  • Penilente LA
  • Penzathine
  • Retarpen
  • Retarpen LA
  • Tardocillin
  • Terbocyl
  • Ultracillin LA
  • Unicil L-A
  • Zalpen

Penicillin G benzathine Brands Names in Pakistan:

Benzathine Penicillin Inj 0.1 Miu

Benzyl Penicillin P.D.H. Pharmaceuticals (Pvt) Ltd.

 

Benzathine Penicillin Injection 0.6 Miu

Benza L-A Macter International (Pvt) Ltd.
Benzibiotic Zafa Pharmaceutical Laboratories (Pvt) Ltd.
Biotic-P English Pharmaceuticals Industries
La Pen P.D.H. Pharmaceuticals (Pvt) Ltd.

 

Benzathine Penicillin Injection 1.2 Miu

Benza L-A Macter International (Pvt) Ltd.
Benzibiotic Zafa Pharmaceutical Laboratories (Pvt) Ltd.
Biotic-P English Pharmaceuticals Industries
La Pen P.D.H. Pharmaceuticals (Pvt) Ltd.

 

Benzathine Penicillin Injection 0.05 Miu

Benzyl Penicillin P.D.H. Pharmaceuticals (Pvt) Ltd.